Nuvation Bio Reports Q3 Revenue Growth Driven by IBTROZI Sales and Outlines European Expansion Plans
Nuvation Bio (NUVB) reported strong third-quarter financial results, highlighted by $45 million in total revenue. A significant driver of this performance was the product IBTROZI, which saw net U.S. product revenue reach $27.5 million, marking an 18% sequential growth rate. Looking ahead, the company is targeting expansion into European markets with a potential regulatory approval expected in the first half of next year. This milestone is anticipated to trigger approximately $30 million in milestone payments, providing further momentum for the company's commercial trajectory.
Tickers: $NUVB